These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29720711)

  • 21. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
    Hertel P
    Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
    Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
    Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
    Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A
    Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
    Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
    Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum.
    Ishikane T; Kusumi I; Matsubara R; Matsubara S; Koyama T
    Eur J Pharmacol; 1997 Feb; 321(2):163-9. PubMed ID: 9063684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
    Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
    J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iloperidone binding to human and rat dopamine and 5-HT receptors.
    Kongsamut S; Roehr JE; Cai J; Hartman HB; Weissensee P; Kerman LL; Tang L; Sandrasagra A
    Eur J Pharmacol; 1996 Dec; 317(2-3):417-23. PubMed ID: 8997630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
    Raviña E; Casariego I; Masaguer CF; Fontenla JA; Montenegro GY; Rivas ME; Loza MI; Enguix MJ; Villazon M; Cadavid MI; Demontis GC
    J Med Chem; 2000 Nov; 43(24):4678-93. PubMed ID: 11101359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
    Ishiyama T; Tokuda K; Ishibashi T; Ito A; Toma S; Ohno Y
    Eur J Pharmacol; 2007 Oct; 572(2-3):160-70. PubMed ID: 17662268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TPN672: A Novel Serotonin-Dopamine Receptor Modulator for the Treatment of Schizophrenia.
    Wang Y; He Y; Yang F; Abame MA; Wu C; Peng Y; Feng L; Shen J; Wang Z; He L
    J Pharmacol Exp Ther; 2021 Jul; 378(1):20-30. PubMed ID: 33975897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
    Liégeois JF; Eyrolles L; Ellenbroek BA; Lejeune C; Carato P; Bruhwyler J; Géczy J; Damas J; Delarge J
    J Med Chem; 2002 Nov; 45(23):5136-49. PubMed ID: 12408724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A study of the structure-affinity relationship in SYA16263; is a D
    Onyameh EK; Bricker BA; Eyunni SVK; Voshavar C; Gonela UM; Ofori E; Jenkins A; Ablordeppey SY
    Bioorg Med Chem; 2021 Jan; 30():115943. PubMed ID: 33338898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
    Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
    Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural analogues of 5-OMe-BPAT: synthesis and interactions with dopamine D2, D3, and serotonin 5-HT1A receptors.
    Homan EJ; Kroodsma E; Copinga S; Unelius L; Mohell N; Wikström HV; Grol CJ
    Bioorg Med Chem; 1999 Jun; 7(6):1111-21. PubMed ID: 10428381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.